Compare TG Therapeutics Inc (TGTX) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs UnitedHealth Group Inc — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while UnitedHealth Group Inc trades at $394.32 (market cap $359.79B). The key difference: UnitedHealth Group Inc is far larger — about 42.2× TG Therapeutics Inc's market cap, and UnitedHealth Group Inc pays a 2.32% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | UNH | |
|---|---|---|
Market Cap | $8.53B | $359.79B |
Sector | Health | Health |
52-Week High | $59.06 | $436.35 |
52-Week Low | $26.94 | $259.02 |
Enterprise Value | $8.74B | $401.65B |
Dividend Yield | — | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
UnitedHealth Group (UNH) trades at $393.06, down 1.03% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported revenue of $447.57B in 2025, with net income of $12.06B, and has beaten EPS estimates in recent quarters. Recent news highlights strategic moves to reduce pediatric prior authorizations and ongoing shareholder returns via dividends and buybacks.
The outlook for UNH is positive, driven by aging demographics, Medicare growth, and operational efficiencies, though risks include regulatory scrutiny and margin pressures. With 82.7% of analysts rating it a buy and a consensus price target of $475.47, the stock presents a compelling opportunity for long-term investors seeking exposure to healthcare stability and dividend growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
